Side Effects of dextromethorphan and quinidine: A Synthesis of Findings from 6 Studies

  1. Home
  2. Side Effects of dextromethorphan and quinidine
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of dextromethorphan and quinidine: A Synthesis of Findings from 6 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of dextromethorphan and quinidine: A Synthesis of Findings from 6 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Key Findings

The combination of dextromethorphan and quinidine has shown efficacy in treating pseudobulbar affect (PBA), a neurological disorder characterized by involuntary and uncontrollable episodes of laughing and/or crying. 4 Quinidine, a component of this combination, inhibits the metabolism of dextromethorphan, increasing its concentration in the bloodstream and enhancing its therapeutic effect. 5 This combination has also shown promise in managing agitation in patients with Alzheimer's disease. 3

Reasons for side effects

Side effects associated with the dextromethorphan and quinidine combination can be attributed to the QT prolongation potential of quinidine, potential for drug interactions, and the inherent side effects of dextromethorphan itself. 4 5

Common side effects

QT prolongation

Quinidine can affect the electrical activity of the heart, leading to a prolongation of the QT interval. 4 5 An extended QT interval increases the risk of irregular heartbeats, potentially leading to life-threatening ventricular fibrillation.

Drug interactions

Quinidine is known to interact with other medications, requiring careful consideration when administered. 4

Other side effects

Dextromethorphan may cause side effects like nausea, vomiting, dizziness, drowsiness, and constipation. 4 5

Side effects management

QT prolongation

For patients at high risk of QT prolongation, a heart examination is recommended before initiating treatment with the dextromethorphan and quinidine combination. 4

Drug interactions

It is crucial to inform the doctor about any other medications being taken before starting the dextromethorphan and quinidine combination. 4

Other side effects

If any side effects occur, consulting a doctor is recommended. 4 5

Comparison of studies

Similarities between studies

Multiple studies have indicated the effectiveness of the dextromethorphan and quinidine combination in managing pseudobulbar affect. 4 5 These studies have also reported potential side effects such as QT prolongation. 4 5

Differences between studies

There are variations in the methods used to assess the efficacy and safety of the dextromethorphan and quinidine combination across different studies. Additionally, the characteristics of patients involved in each study vary, making direct comparisons of study results challenging. 4 5 3

Practical implications and considerations

The dextromethorphan and quinidine combination holds potential for treating pseudobulbar affect, but it comes with potential side effects such as QT prolongation. 4 5 Consulting a doctor and weighing the risks and benefits is crucial before using this medication. 4 5

Limitations of current research

There is a need for more extensive research on the dextromethorphan and quinidine combination. 4 5

Future research directions

Further research is needed to investigate the long-term safety and efficacy of the dextromethorphan and quinidine combination. 4 5 Research aimed at determining the optimal dosage and administration methods for this medication is also crucial.

Conclusion

While the dextromethorphan and quinidine combination shows promise in managing pseudobulbar affect, it's essential to be aware of potential side effects such as QT prolongation. 4 5 Before using this medication, careful consultation with a doctor and thorough assessment of the risks and benefits are essential.

Literature analysis of 6 papers
Positive Content
6
Neutral Content
0
Negative Content
0
Article Type
1
0
0
4
6
1.

[Genetic and environmental effects on neuromodulation and the antinociceptive effect of dextromethorphan].

Author: OestreicherM K, DesmeulesJ, PiguetV, AllazA F, DayerP

Antinociceptive effect
Neuromodulatory effects
CYP2D6 phenotype

Dextromethorphan and its metabolite dextrophan were found to have antinociceptive and neuromodulatory effects. The effects were heavily dependent on the cytochrome P450 2D6 phenotype (CYP2D6).

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : French

4.

Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect.

Author: SchoedelKerri A, MorrowSarah A, SellersEdward M

PBA treatment
Drug interactions
QT prolongation

Dextromethorphan/quinidine (DM/Q) is a combination product indicated for the treatment of pseudobulbar affect (PBA). Three studies have shown significant effects on the primary end point, the Center for Neurologic Study-Lability Scale, and secondary efficacy endpoints.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

6.

AVP-786 as a promising treatment option for Alzheimer's Disease including agitation.

Author: KhouryRita, MarxCharlotte, MirgatiSidney, VeluryDivya, ChakkamparambilBinu, GrossbergGeorge T

Agitation treatment

This review examines AVP-786, a deuterated form of dextromethorphan/quinidine, as a potential treatment for agitation in Alzheimer's disease (AD). AVP-786 has shown promise as a safe and potentially effective treatment for agitation in AD. While phase III trials showed mixed findings, future studies with improved study designs and assessments are needed to further evaluate its efficacy and safety.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.